Tags

Type your tag names separated by a space and hit enter

Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp).
Horm Metab Res. 1995 Sep; 27(9):421-4.HM

Abstract

In this double blind randomized study we compared the insulinkinetic, insulindynamic and the frequency of hypoglycemic events after s.c. injection of human insulin and the insulin analogue (B28Asp). Fourteen c-peptide negative patients treated with continuous subcutaneous insulin infusion (CSII) were included in the study. Their mean age was 42.9 (range 26-60 yrs), duration of diabetes 18.5 (5-29) and mean duration of CSII 6.3 yrs (3-10). Serum free insulin (FIRI) was determined from 8:00 to 11:00 h, and blood glucose from 7:00 to midnight. Maximum FIRI values were obtained after 45 min for (B28Asp) and after 90 min for Actrapid HM. Maximum blood glucose increase (Tmax) was obtained 60 min after injection of (B28Asp) and 90 min after Actrapid HM. The AUCBC was greater after administration of Actrapid HM compared to (B28Asp) (p < or = 0.05). A total number of 16 hypoglycemias (BG < or = 3.3 mmol.l-1) were registered. 8 episodes were induced equally by (B28Asp) and by Actrapid HM. We conclude that in insulin dependent diabetic patients the insulin analogue (B28Asp) showed a faster absorption and less hyperinsulinemia than Actrapid HM after s.c. administration. The corresponding BG-values were higher after s.c. administration of Actrapid HM compared to (B28Asp). These findings in patients support the concept of a more physiological effect of rapid acting insulin analogues than of regular insulin.

Authors+Show Affiliations

Wiefels K
Diabetes-Forschungsinstitut an der Heinrich Heine Universität Düsseldorf, Germany.
Hübinger A
No affiliation info available
Dannehl K
No affiliation info available
Gries FA
No affiliation info available

MeSH

AdultBlood GlucoseCross-Over StudiesDiabetes Mellitus, Type 1Double-Blind MethodFemaleHumansHypoglycemiaHypoglycemic AgentsInfusion Pumps, ImplantableInsulinInsulin AspartInsulin Infusion SystemsMaleMiddle Aged

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8557242

Citation

Wiefels, K, et al. "Insulinkinetic and -dynamic in Diabetic Patients Under Insulin Pump Therapy After Injections of Human Insulin or the Insulin Analogue (B28Asp)." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 27, no. 9, 1995, pp. 421-4.
Wiefels K, Hübinger A, Dannehl K, et al. Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp). Horm Metab Res. 1995;27(9):421-4.
Wiefels, K., Hübinger, A., Dannehl, K., & Gries, F. A. (1995). Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp). Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 27(9), 421-4.
Wiefels K, et al. Insulinkinetic and -dynamic in Diabetic Patients Under Insulin Pump Therapy After Injections of Human Insulin or the Insulin Analogue (B28Asp). Horm Metab Res. 1995;27(9):421-4. PubMed PMID: 8557242.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp). AU - Wiefels,K, AU - Hübinger,A, AU - Dannehl,K, AU - Gries,F A, PY - 1995/9/1/pubmed PY - 1995/9/1/medline PY - 1995/9/1/entrez SP - 421 EP - 4 JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme JO - Horm Metab Res VL - 27 IS - 9 N2 - In this double blind randomized study we compared the insulinkinetic, insulindynamic and the frequency of hypoglycemic events after s.c. injection of human insulin and the insulin analogue (B28Asp). Fourteen c-peptide negative patients treated with continuous subcutaneous insulin infusion (CSII) were included in the study. Their mean age was 42.9 (range 26-60 yrs), duration of diabetes 18.5 (5-29) and mean duration of CSII 6.3 yrs (3-10). Serum free insulin (FIRI) was determined from 8:00 to 11:00 h, and blood glucose from 7:00 to midnight. Maximum FIRI values were obtained after 45 min for (B28Asp) and after 90 min for Actrapid HM. Maximum blood glucose increase (Tmax) was obtained 60 min after injection of (B28Asp) and 90 min after Actrapid HM. The AUCBC was greater after administration of Actrapid HM compared to (B28Asp) (p < or = 0.05). A total number of 16 hypoglycemias (BG < or = 3.3 mmol.l-1) were registered. 8 episodes were induced equally by (B28Asp) and by Actrapid HM. We conclude that in insulin dependent diabetic patients the insulin analogue (B28Asp) showed a faster absorption and less hyperinsulinemia than Actrapid HM after s.c. administration. The corresponding BG-values were higher after s.c. administration of Actrapid HM compared to (B28Asp). These findings in patients support the concept of a more physiological effect of rapid acting insulin analogues than of regular insulin. SN - 0018-5043 UR - https://www.unboundmedicine.com/medline/citation/8557242/Insulinkinetic_and__dynamic_in_diabetic_patients_under_insulin_pump_therapy_after_injections_of_human_insulin_or_the_insulin_analogue__B28Asp__ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓3]

Related Citations

More